2 completed, 1 unknown. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Unknown 1 |
| Phase 2 | 1 | Completed 1 |
Follow D5W Placebo: new trials by email Literature Review of D5W Placebo trials Research Report on D5W Placebo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia Pegfilgrastim, Plinabulin, D5W Placebo - Chemotherapy-induced Neutropenia | Phase 3 | Unknown | BeyondSpring Pharmaceuticals Inc. | 221 | 2019-10-23 | 2021-01-15 |
| Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3 Plinabulin, Pegfilgrastim, Saline Placebo - Chemotherapy-induced Neutropenia | Phase 3 | Completed | BeyondSpring Pharmaceuticals Inc. | 105 | 2018-05-29 | 2024-08-29 |
| N-Acetylcysteine in Critically Ill Patients Undergoing Contrast Enhanced Computed Tomography N-acetylcysteine, D5W Placebo - Contrast Induced Nephropathy, Critically Ill | Phase 2 / Phase 3 | Completed | Unity Health Toronto | 45 | 2002-08-01 | 2009-01-27 |
Critical Illness (1)
BeyondSpring Pharmaceuticals Inc. (2) · Unity Health Toronto (1)
China (2) · Ukraine (2) · Canada (1) · Russia (1) · United States (1)
Claudio M Martin, MD, FRCPC, MSc (1) · Douglas Blayney, M.D. (1) · Douglas W. Blayney, MD (1)